Using blood tests and BRAF testing to assess thyroid nodules
To Reveal the Predictive Value of Preoperative Hemogram Parameters and BRAF Molecular Test in Predicting Malignancy in Cases With Thyroid Nodules Detected by Bethesda 3 Cytology.
Saglik Bilimleri Universitesi · NCT06539702
This study is testing if certain blood tests and BRAF testing can help doctors determine if thyroid nodules are cancerous in patients, aiming to avoid unnecessary surgeries.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 120 (estimated) |
| Ages | 18 Years to 75 Years |
| Sex | All |
| Sponsor | Saglik Bilimleri Universitesi (other) |
| Locations | 1 site (Istanbul) |
| Trial ID | NCT06539702 on ClinicalTrials.gov |
What this trial studies
This observational study investigates whether preoperative hemogram parameters can serve as biomarkers for malignancy in patients with thyroid nodules classified as Bethesda 3. It also examines the predictive value of BRAF molecular testing in these patients. The study aims to reduce unnecessary thyroid surgeries and associated complications by accurately identifying malignancy risk. Key parameters such as Mean Platelet Volume, Neutrophil/Lymphocyte Ratio, and others will be recorded, along with nodule sizes and outcomes post-thyroidectomy.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 to 75 diagnosed with Bethesda III thyroid nodules who are planning to undergo thyroidectomy.
Not a fit: Patients outside the age range of 18 to 75 or those with malignancy detected in other areas will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could help avoid unnecessary thyroid surgeries and reduce treatment costs for patients with Bethesda 3 thyroid nodules.
How similar studies have performed: While the approach of using hemogram parameters and BRAF testing is promising, it is not widely tested in this specific context, making this study relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Patients between the ages of 18 -75 2. Patients who were diagnosed with Bethesda III as a result of preoperative FNAC and decided to undergo thyroidectomy Exclusion Criteria: 1. Patients over 18 years old and under 75 years old 2. Patients with malignancy detected in another focus with preoperative Bethesda III FNAC 3. Detection of malignancy in another focus other than the nodule with Bethesda III cytological result after thyroidectomy 4. Failure to obtain preoperative hemogram results Patients who do not agree to participate in scientific studies for BRAF testing
Where this trial is running
Istanbul
- Prof. Dr. Cemil Tascioglu City Hospital — Istanbul, Turkey (Türkiye) (RECRUITING)
Study contacts
- Principal investigator: Ugur Kesici, Assoc.Prof. — Prof. Dr. Cemil Tascıoglu Education and Research Hospital Organization
- Study coordinator: Ugur 1 Kesici, Assoc. Prof.
- Email: ugur.kesici@sbu.edu.tr
- Phone: 00905445474710
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Blood Platelet Disorder, BRAF V600E, Thyroid Nodule, Cytologic Atypia, Thyroid, carcinoma, Bethesda 3, BRAF